Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 25Recruiting 13Not yet recruiting 7Active not recruiting 6Withdrawn 3Unknown 3Terminated 2Enrolling by invitation 1Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × PM 01183 × Clear all
NCT05126433 2025-02-28

JAZZ EMERGE201

Jazz Pharmaceuticals

Phase 2 Terminated
47 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04610658 2024-04-02

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
9 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡